Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
1
25%
Ph not_applicable
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Completed1
Recruiting1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
N/A2 (50.0%)

Trials by Status

completed125%
recruiting125%
withdrawn125%
terminated125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

Fecal Microbiota Transplantation for IBS

NCT05776914
terminatednot_applicable

The IRMI-FMT Trial

NCT04577729
completedphase_1

PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

NCT02928523
withdrawnnot_applicable

Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease

NCT03492502

Clinical Trials (4)

Showing 4 of 4 trials
NCT05776914Phase 2

Fecal Microbiota Transplantation for IBS

Recruiting
NCT04577729Not Applicable

The IRMI-FMT Trial

Terminated
NCT02928523Phase 1

PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

Completed
NCT03492502Not Applicable

Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4